Aprepitant: Mechanism of action, Side effects and Pharmacokinetics
Aprepitant is a neurokinin-1 receptor antagonist that, in combination with a glucocorticoid and a 5HT3 receptor antagonist, is very effective in preventing chemotherapy-induced nausea and vomiting.
Nov 20，2024 API
Ferulic Acid: An Overview of Its Synthesis, Composition, Applications, and Storage
Ferulic acid, a key phenolic compound, plays a crucial role in the biosynthesis of plant cell walls.
Nov 20，2024 Natural Products
Dapagliflozin: A Breakthrough in Diabetes Management and Beyond
Dapagliflozin, has emerged as a pivotal player in the management of type 2 diabetes mellitus.
Nov 20，2024 API
What is the Pharmacokinetics of Dabigatran etexilate mesylate?
Dabigatran etexilate mesylate, also known by its brand name, Pradaxa, is a type of anticoagulant blood thinner that treats and prevents certain types of blood clots in people ages 8 years and older.
Nov 20，2024 API
Paeonol: Chemical Properties, Biological Activities, and Applications in Pharmaceuticals and Cosmetics
Paeonol has garnered significant attention in the chemical and pharmaceutical industries due to its broad spectrum of biological activities.
Nov 20，2024 API
Is Carbon tetrabromide a polar or nonpolar compound?
Carbon tetrabromide (CBr4) is a non-polar molecule with the same polarity as the CO? molecule.
Nov 19，2024 API
Ammonium lauryl sulfate: Applications and Toxic Mechanism
Ammonium lauryl sulfate enhances fuel cells and latex production but poses health risks due to mitochondrial-induced apoptosis.
Nov 19，2024 API
Baricitinib: Clinical Efficacy and Safety
Baricitinib is effective for Alopecia Areata and has a favorable safety profile, supporting its use in atopic dermatitis treatment.
Nov 19，2024 API
Ketorolac Tromethamine Injection and Ketorolac tromethamine tablets
Ketorolac tromethamine (Acular), approved in November 1992, is one of the earliest prescription products for treating itch associated with allergic conjunctivitis.
Nov 19，2024 API
Brigatinib: Development History and Preclinical Studies
Brigatinib, a crucial treatment for NSCLC patients with EGFR and ALK mutations, effectively inhibits ALK with unique features, overcoming resistance and offering hope in lung cancer treatment.
Nov 19，2024 API